Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 4/20 | 0.50 |
| ▸ | YAP1 | P46937 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24497427 | 1.00 | TEAD1 (0.50) | TEAD1YAP1PTGS1TRPV1KCNH2 | |
| SCHEMBL25877140 | 0.85 | TEAD1 (0.67) | TEAD1YAP1LRRK2TSHRL3MBTL1 | |
| SCHEMBL30503081 | 0.85 | TEAD1 (0.67) | TEAD1YAP1LRRK2TSHRL3MBTL1 | |
| SCHEMBL24500992 | 0.85 | TEAD1 (0.48) | TEAD1YAP1TRPV1KCNH2GABRA1 | |
| SCHEMBL24501728 | 0.84 | TEAD1 (0.61) | TEAD1YAP1TRPV1KCNH2GABRA1 | |
| SCHEMBL24790230 | 0.84 | TEAD1 (0.50) | TEAD1YAP1TRPV1KCNH2GABRA1 | |
| SCHEMBL24496101 | 0.83 | TEAD1 (0.49) | TEAD1YAP1PTGS1TRPV1KCNH2 | |
| SCHEMBL24501068 | 0.82 | TEAD1 (0.61) | TEAD1YAP1KCNH2GABRA1GABRG2 | |
| SCHEMBL24496100 | 0.81 | TLR2 (0.51) | TEAD1YAP1PTGS1TRPV1KCNH2 | |
| SCHEMBL22718190 | 0.81 | TEAD1 (0.77) | TEAD1YAP1TSHRL3MBTL1MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240261288-A1 | COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER | THE EHE FOUNDATION | 2024-08-08 | — | — | US | disclosed |
| CN-117561061-A | Combination of 3- (imidazol-4-yl) -4- (amino) -benzenesulfonamide TEAD inhibitors with EGFR inhibitors and/or MEK inhibitors for the treatment of lung cancer | 医肯纳肿瘤学公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117015531-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-4255895-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022120355-A1 | TEAD DEGRADERS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022120354-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261288-A1 | COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER | EGFR, ERBB2, ERBB4 | TEAD1 20/4885YAP1 430/4885PTGS1 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.